Acute myeloid leukaemia at the extremes The Lancet Haematology +++ +...

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/abstract?dgcid=raven_jbs_etoc_feature_lanhae Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00295-9/abstract?dgcid=raven_jbs_etoc_feature_lanhae Acute myeloid leukaemia at the extremes The Lancet Haematology https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00326-6/fulltext?dgcid=raven_jbs_etoc_email Dec 2025 Volume 12Number 12e927-e986 https://www.thelancet.com/journals/lanhae/issue/vol12no12/PIIS2352-3026(25)X0012-0